IceCure Medical Reports 42% Sales Jump in North America
Ticker: ICCM · Form: 6-K · Filed: Jan 13, 2025 · CIK: 1584371
Sentiment: bullish
Topics: sales-growth, medical-devices, press-release
TL;DR
IceCure Medical's ProSense sales in North America surged 42% in 2024!
AI Summary
On January 13, 2025, IceCure Medical Ltd. announced a 42% increase in ProSense® sales for 2024 in North America, as detailed in a letter from their CEO to shareholders. The company is a foreign private issuer filing a Form 6-K report for January 2025.
Why It Matters
This significant sales growth in a key market suggests increasing adoption of IceCure's medical technology, potentially indicating strong future revenue performance.
Risk Assessment
Risk Level: medium — While sales growth is positive, the filing is a routine report and doesn't detail financial health or future outlook beyond this specific metric.
Key Numbers
- 42% — ProSense® Sales Increase (Year-over-year growth in North America for 2024)
Key Players & Entities
- IceCure Medical Ltd. (company) — Registrant
- ProSense® (product) — Product with increased sales
- January 13, 2025 (date) — Date of press release and filing
- North America (location) — Region of sales increase
FAQ
What is the specific revenue figure associated with the 42% increase in ProSense® sales for 2024 in North America?
The filing does not provide the specific revenue figure, only the percentage increase.
Who is the CEO of IceCure Medical Ltd. that issued the letter to shareholders?
The filing mentions a letter from the CEO but does not state their name.
What is the primary business of IceCure Medical Ltd.?
IceCure Medical Ltd. is in the business of surgical and medical instruments and apparatus, specifically mentioning their ProSense® product.
What is the significance of filing a Form 6-K?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the company has made or is required to make public pursuant to the laws of its home country.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Filing Stats: 306 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2025-01-13 07:16:40
Filing Documents
- ea022734603-6k_icecure.htm (6-K) — 11KB
- ea022734603ex99-1_icecure.htm (EX-99.1) — 28KB
- 0001213900-25-002825.txt ( ) — 40KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ICECURE MEDICAL LTD. Date: January 13, 2025 By: /s/ Eyal Shamir Name: Eyal Shamir Title: Chief Executive Officer 2